WALTHAM, Mass., July 22, 2026 /PRNewswire/ -- Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, today announced a $200 million private placement to leading healthcare investors.
Former Avadel CEO brings a proven track record of strategic leadership, M&A expertise, and commercial success to lead Mentari as it advances potentially best-in-class therapies for the prevention of migraine Mentari is on-track for regulatory filings to support the advancement of MT-001, an
Mentari's parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapies Concurrent oversubscribed US$290 million private placement of Mentari expected to fund company operations through 2028
